Jazz Pharmaceuticals (JAZZ) Cash from Financing Activities (2010 - 2026)

Jazz Pharmaceuticals' Cash from Financing Activities history runs 17 years deep, the most recent figure standing at -$78.5 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities rose 90.35% year-over-year to -$78.5 million in Q1 2026; TTM through Mar 2026 was -$138.4 million, a 81.21% increase from a year earlier, with the FY2025 full-year figure at -$873.4 million, down 4357.07% from the prior year.
• Cash from Financing Activities fell to -$78.5 million in Q1 2026 per JAZZ's latest filing, from $75.4 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $246.4 million in Q3 2024 and bottomed at -$813.5 million in Q1 2025.
• The 5-year median for Cash from Financing Activities is -$78.5 million (2023), against an average of -$103.9 million.
• Across the five-year window, Cash from Financing Activities plunged 1581.78% in 2022 and jumped 1011.66% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $19.6 million in 2022, then plunged by 611.87% to -$100.3 million in 2023, then soared by 91.75% to -$8.3 million in 2024, then soared by 1011.66% to $75.4 million in 2025, then slumped by 204.06% to -$78.5 million in 2026.
• Per Business Quant, the three latest JAZZ Cash from Financing Activities figures stand at -$78.5 million (Q1 2026), $75.4 million (Q4 2025), and -$10.8 million (Q3 2025).